AKAli̇ Riza Kandi̇lOğlu

Ali̇ Riza Kandi̇lOğlu

*This is an algorithmically generated author record based on publicly available information.

Ali̇ Riza Kandi̇lOğlu has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prognostic significance and clinicopathological associations of tumor budding and poorly differentiated clusters in endometrioid endometrial carcinoma

    by Hani̇fE Seda Mavi̇lİ, Ömer Atmiş, Fatma Seher Pehli̇vAn, Fatma Sezen Çavdaroğlu Deveci̇, Ali̇ Riza Kandi̇lOğlu

    Background/aim: Tumor budding (TB) and poorly differentiated clusters (PDCs) are histopathological parameters that have been associated with poor prognosis in various malignancies, particularly colorectal carcinoma. Although numerous studies have demonstrated an association between the microcystic, elongated, and fragmented (MELF) pattern in endometrial carcinomas and lymphovascular invasion as well as lymph node metastasis, the literature regarding TB and PDCs in this context remains limited. This study aimed to investigate the potential associations of the MELF pattern, TB, and PDCs with overall survival, progression-free survival, and clinicopathological parameters in cases of endometrioid endometrial carcinoma (EEC). Materials and methods: A total of 190 cases diagnosed with EEC through hysterectomy specimens between 2010 and 2023, with complete hospital records, were selected from the archives of the Department of Pathology at Manisa Celal Bayar University Faculty of Medicine. Results: The presence of TB and PDCs was significantly associated with high histological grade (p < 0.001), deep myometrial invasion (p < 0.001), lymphovascular invasion (p < 0.001), lymph node metastasis (p < 0.001), cervical stromal involvement (p < 0.001), serosal involvement (p < 0.001), advanced stage (p < 0.001), and larger tumor size (p = 0.042 and p = 0.027, respectively). The presence of TB and PDCs was found to be associated with reduced overall survival (p = 0.001 and p < 0.001, respectively) and reduced progression-free survival (p = 0.043 and p = 0.004, respectively). The MELF pattern was not significantly associated with overall survival (p = 0.772). Conclusion: These findings suggest that the presence of TB and PDCs may be valuable in stratifying prognostic risk in EEC and support the inclusion of these parameters in routine pathology reporting.

  • Evaluation of the concordance of ER, PR, HER2, and Ki-67 expression levels between primary breast tumors and their liver metastases: a retrospective analysis of 57 cases

    by Ömer Atmış, Hanife Seda Mavili, Fatma Seher Pehlivan, Ali Rıza Kandiloğlu, Semin Ayhan

    Purpose: This study aims to evaluate the changes in estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 expression between primary breast tumors and their liver metastases. Materials and methods: A total of 57 patients with breast cancer liver metastases were included. Immunohistochemical staining was performed to assess ER, PR, HER2, and Ki-67 expression in both primary and metastatic tumors. HER2 status was confirmed by silver in situ hybridization (SISH) when necessary. Statistical analyses were conducted to evaluate changes in biomarker expression. Results: Comparison of biomarker expression between primary and metastatic biopsies revealed changes in ER status in 5 cases (1 from negative to positive, 4 from positive to negative); PR status in 22 cases (4 from negative to positive, 18 from positive to negative); HER2 status in 5 cases (2 from negative to positive, 3 from positive to negative); and Ki-67 status in 13 cases (6 from low to high, 7 from high to low). The discordance rates for ER, PR, HER2, and Ki-67 were calculated as 8.8%, 38.6%, 8.8%, and 28.9%, respectively. Conclusion: Our findings confirm that biomarker expression may change between primary and metastatic breast cancer lesions. Given the crucial role of receptor status in treatment decisions, re-biopsy of metastatic lesions is essential to guide personalized therapy.